Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06636123
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-08
Brief Title:
GZ17-602 in Advanced CRPC After Progression on Anti-Androgen Therapy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
GZ17-602 in Advanced Castration-Resistant Prostate Cancer CRPC After Progression on Anti-Androgen Therapy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical trial is to determine if GZ17-602 delays progression of castration-resistant prostate cancer
Detailed Description:
This single-arm phase Ib study will assess whether GZ17-602 a combination of curcumin harmine and isovanillin delays radiographic progression of castration-resistant prostate cancer among men previously treated with androgen deprivation therapy and an androgen receptor pathway inhibitor All participants in the study will receive GZ17-602 The study will also assess the safety and tolerability of GZ17-602 and explore patient-reported outcomes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None